Sanofi Goes All The Way In mRNA With Translate Bio Buy
French Giant Paying $3.2bn
Executive Summary
Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.
You may also be interested in...
Stock Watch: Sanofi’s Vaccine Gap-Filling Aspirations
Phase II studies of vaccines involve more variables than for drugs and these can be compounded by seasonality. This can make the time until vaccine approval longer than would be expected for drugs.
Cipla Moves Into mRNA Arena With Stake In German Biotech Ethris
Cipla set to hold 10.35% in biotech Ethris, which is progressing inhaled mRNA-based therapies, among other key assets. The Indian firm expects its next wave of growth to come from areas like biosimilars and mRNA alongside lung leadership aspirations, putting the spotlight on the broader direction of the deal.
AI/ML Grows In Importance, Holds Promise in mRNA
Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.